Kornimate/medical-research-clean huggingface dataset:
flatbush fhc proactive colorectal cancer screening and navigation

Conditions: Colorectal Cancer

Summary: the proposed study is a randomized controlled pilot trial designed to assess the effectiveness and acceptability of a proactive screening outreach program on colorectal cancer screening rates on eligible patients in the flatbush family health center medical practice.

the proposed study is a randomized controlled pilot trial designed to assess the effectiveness and acceptability of a proactive screening outreach program on colorectal cancer screening rates on eligible patients in the flatbush family health center medical practice, which provides free and subsidized health services to underrepresented minorities. the investigators will randomize patients to the proactive screening outreach arm which will include mailed letters providing patients with information regarding their eligibility for and instructions for performing colorectal cancer screening with fit testing or colonoscopy. colorectal cancer screening rates via fit testing or colonoscopy will be compared in the proactive outreach group and the usual care group. the investigators hypothesize that rates of colorectal cancer screening will improve in underserved populations with the implementation of a proactive approach that incorporates a mailed outreach invitation to screen, followed by active assistance to a colonoscopy completion if preferred or indicated.

Eligibility criteria:
inclusion criteria: * receiving medical care at flatbush fhc * due or overdue for crc screening exclusion criteria: * age younger than 45 years old or greater than 75 years old * up-to-date with colorectal cancer screening (fit within 1 year or colonoscopy within 10 years) * history of colorectal cancer, inflammatory bowel disease or colorectal polyps * no address or phone number on file * fit test ordered within 6 months
vaxzevria japan post-marketing surveillance (pms) for the long-term safety of vaxzevria

Conditions: Prevention of Infectious Disease Caused by SARS-CoV-2

Summary: this survey will be conducted for the subjects who participate in the priority survey (cohort survey) conducted by the scientific research group of the ministry of health, labour and welfare at the initial stage of administration of the covid-19 vaccination. the present study aims to collect information on serious adverse events or covid-19 infection observed from 28 days after the last vaccination of vaxzevria up to 12 months after the last vaccination and to evaluate the long-term safety of this vaccine.

this survey will be conducted for the subjects who participate in the priority survey (cohort survey) conducted by the scientific research group of the ministry of health, labour and welfare at the initial stage of administration of the covid-19 vaccination. the present study aims to collect information on serious adverse events (including thrombosis in combination with thrombocytopenia, immune-mediated neurological conditions, vaccine-associated enhanced disease (vaed) including vaccine-associated enhanced respiratory disease(vaerd), thrombosis or other diseases) or covid-19 infection observed from 28 days after the last vaccination of vaxzevria up to 12 months after the last vaccination and to evaluate the long-term safety of this vaccine.

Eligibility criteria:
inclusion criteria: the subjects who participated in the cohort study conducted by the scientific research group of the mhlw and those who give written consents for this study. exclusion criteria: none
direct peritoneal resuscitation effects in the damage control patient

Conditions: Traumatic Injury

Summary: the purpose of this study is to find if direct peritoneal resuscitation helps blood flow through important organs in a person's body after they have had a traumatic injury with massive blood loss. sometimes after severe injuries requiring operation, surgeons cannot close the muscles and skin of a patient's belly, because of swelling. this study will also try to find if direct peritoneal resuscitation decreases tissue swelling and allows for quicker closure of of a patient's belly.

standard methods of controlling bleeding and increasing blood flow to vital organs will be used. these methods include giving blood and fluids and surgically repairing the vessels that are causing the bleeding which are standard ways physicians treat injuries with massive blood loss. a drain (a small plastic tube) will be placed inside the belly. subjects will randomly (like flipping a coin) be placed into a group of patients who either get a sugar solution dripped into the belly after surgery or do not get this treatment. the drain will be used to drip a high glucose solution into the abdomen in patients be part of that group. the fluid will continue to be dripped into the belly until it is possible to close the skin and underlying layers.

Eligibility criteria:
inclusion criteria: * all trauma patients age 18 years or greater with massive blood loss * patients requiring a damage control procedure * traumatic injury within the last 24 hours exclusion criteria: * patients who are pregnant * less than 18 years of age * known chronic renal disease * moribund

Keywords: trauma hypovolemia
music therapy in sickle cell transition study

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to investigate the effects of the beats music therapy program on the self-efficacy, trust, knowledge, and adherence of young adult patients with sickle cell disease during transition. primary hypotheses: compared to baseline, young adult patients with sickle cell disease who receive the music therapy interventions will report: 1. higher sickle cell self-efficacy as measured by the sickle cell self efficacy scale (scses), 2. higher trust in health care providers as measured by the wake forest trust in the medical profession scale, and 3. higher sickle cell disease knowledge as measured by the seidman sickle cell knowledge quiz. secondary hypotheses 1. compared to the one year prior to the study period, young adults with sickle cell disease who receive the music therapy interventions will have a higher rate of adherence to clinic appointments during the one-year study period. additional questions 1. do music therapy interventions influence attendance to scheduled blood transfusions? 2. do music therapy interventions influence the rate of hospital utilization as measured by emergency department visits, acute care clinic visits, and admissions during the study period compared to the previous year? 3. do music therapy interventions influence adherence to hydroxyurea therapy for patients receiving hydroxyurea as measured by change in mean corpuscular volume (mcv) during the study period? 4. do music therapy interventions influence adherence to iron chelation therapy for patients receiving iron chelation therapy as measured by ferritin count during the study period?


Eligibility criteria:
inclusion criteria: * subject is between 18 and 23 years of age * subject is diagnosed with sickle cell disease * subject is able to speak and understand english * subject is currently scheduled for quarterly appointments in the bridge clinic exclusion criteria: * subject has significant hearing impairment that has not been corrected * subject has significant visual impairment that has not been corrected
synergistic effect of plasmid inhibitors and antimicrobial drugs against clinical mdr-hvkp

Conditions: Synergy Between Plasmid Inhibitors and Combined Antibiotics

Summary: 1. screening for mdr-hvkp causing vap in patients admitted to chest icu in assiut university hospital. 2. in vitro evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin against clinical mdr-hvkp isolates by checkerboard and time killing assay. 3. in vivo evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin using mdr-hvkp septic rat model.

new "hypervirulent" klebsiella-pneumoniae (hvkp) strain has emerged as a clinically-significant-pathogen in both healthy and immunocompromised individuals . hvkp, at its discovery, was rarely resistant to antimicrobial-agents , however, nowadays, antibiotic-resistant hvkp isolates are being reported . plasmids are important vectors that bacteria use to transfer resistance and virulence determinants. typically, genetic elements conferring resistance and virulence were encoded by different plasmids . most recently, clinicians have been faced, the confluence of resistance and virulence-determinants on the same or coexisting-plasmids with the evolution of multidrug-resistant (mdr) and hypervirulent klebsiella pneumoniae hvkp . one approach to combat mdr infections is to combine antimicrobial drugs during a treatment-regimen . fluoroquinolone plus carbapenems is one of-the most useful-combination used in cases which suffer from mdr to most available monotherapies . another-approach is plasmid curing, using plasmid inhibitors, which is the method of removing plasmids from the bacterial populations while leaving the population intact leading to reversal of the plasmid-mediated antibiotic resistance . kasugamycin, an-aminoglycoside; is a compound exhibiting significant-antiplasmid activity-up-to-complete suppression of plasmid-replication . kasugamycin was found to block plasmid replication by inhibiting-expression of plasmid replication initiation-protein, repe, and to reduce plasmid-levels by 90% . accordingly, we hypothesize that, using dual-antibiotics supplemented with plasmid inhibitor will be efficient in inhibiting mdr-hvkp, both in vitro and in vivo. this is the first-study to evaluate the effect of addition of plasmid inhibitor on improving the efficacy of antibiotics and improve their synergistic activity. the results of this study will open the door for-using plasmid-inhibitor-compounds on restoring the usefulness of many conventional-antibiotics to which-resistance has emerged.

Eligibility criteria:
inclusion criteria: vap patients (patients under mechanical ventilation for more than 48 h with new or progressive infiltrate on chest x-ray and have at least two of the following criteria: 1. fever (\>38 oc) with no other recognized cause 2. wbcs \ 12000/mm3 3. new onset of purulent sputum. 4. increase in respiratory secretion or increased need for suctioning. 5. new-onset or worsening cough, or dyspnea, or tachypnea worsening gas exchange. exclusion criteria: patients with chest diseases other than vap .
immunity after covid-19 vaccination

Conditions: Tunis Military Hospital Staff Vaccinated Against Covid 19

Summary: the purpose of the research is to evaluate kinetic after vaccination to the covid-19 coronavirus by measurements of specific and neutralizant antibodies for spike antigenic sequences . this work will allow us to follow the efficacy and tolerance of the vaccine over a year, to evaluate the antibody profile, their kinetics, the fraction of neutralising antibodies and will also allow us to understand the attitudes to be taken to ensure the best protection for our staff

our objective is to follow the hospital staff after vaccination, for this we will include two groups of participants: g1: vaccinated staff who did not contract the virus (at the date of vaccination) and who had a serology \<0 at least at d7 of the date of vaccination dose 1 (known serological value) g2: vaccinated personnel who have contracted the virus with a pcr + and who have positive serology at least at d7 of the date of vaccination (known serological value)

Eligibility criteria:
inclusion criteria: rb-approved informed consent, age 18 years or older, male or female, anyone considering covid-19 vaccination or anyone that has received covid-19 vaccination. subjects can enroll at anytime after vaccination even though they may not have enrolled before vaccination. sampling frequency and timing: up to 8 total samples in 12 months - exclusion criteria: exclusion: failure to provide informed consent -
scoliosis survey to development treatment decision tool

Conditions: Scoliosis; Adolescence

Summary: this is a survey to help understand the influences related to the decision for adolescent idiopathic scoliosis treatment (observation vs. bracing vs. surgery). the investigator then plans to create a decision aid to help families when making a decision about the treatment choice being presented to them.

this survey is designed to help understand the factors that families consider to help make treatment decisions related to adolescent idiopathic scoliosis (ais). the surveys will then be used to help create a shared decision making tool to help families better understand the treatment options and optimize clinical conversations surrounding ais treatment.

Eligibility criteria:
inclusion criteria: * subject (and/or parent of subject) who has previously been treated for adolescent idiopathic scoliosis (ais) exclusion criteria: * age less than or equal to 12 years
effects of p38 mapk inhibitor polb 001 on in vivo lps challenge responses

Conditions: Influenza, Human

Summary: a single center trial to evaluate the effect of polb 001 on inflammatory responses following an intradermal lps challenge in healthy volunteers.


Eligibility criteria:
inclusion criteria: 1. healthy male volunteers aged 18 to 55 years, inclusive. 2. bmi in the range of 18 to 32 kg/m2 a minimum body weight of 50 kg. 3. fitzpatrick skin type i-iii. 4. able to give written informed consent and willing to comply with all study-related procedures. 5. has the ability to communicate well with the investigator in the dutch language and willing to comply with the study restrictions. exclusion criteria: 1. (a history of) any clinically significant medical condition or abnormalities, as judged by the investigator. 2. history of sepsis, cardiovascular disease or malignancy. 3. history of trauma with likely damage to the spleen or surgery to spleen. 4. history of alcohol or drug abuse. 5. any clinically significant febrile illness 30 days preceding study day 1. 6. history of serious bleeding. 7. clinical evidence of significant or unstable medical illness including neurological, hematological, cardiovascular (including clinically significant arrhythmia), hepatic, pulmonary, metabolic, gastrointestinal, renal, psychiatric, endocrine, or infectious diseases or malignancies. subjects who have had splenectomy. 8. previous participation in a systemic (i.v./inhaled) lps challenge trial within a year before the first study day. 9. have any current and / or recurrent pathologically, clinically significant skin condition at the lower forearms (i.e., atopic dermatitis) including tattoos. 10. antibiotic use, operation or intervention by surgeon/dentist within one month before the first study day. 11. subjects who have used any prescribed or non-prescribed systemic or topical medication (including herbal remedies) within 7 days of the first dose administration, or less than 5 half-lives (whichever is longer), and during the study (except for vitamin/mineral supplements) unless, in the opinion of the investigator, the medication will not interfere with the study procedures or compromise safety. 12. subjects who have received any medications, including st john's wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration unless, in the opinion of the investigator, the medication will not interfere with the study procedures or compromise safety. 13. any active inflammatory or infectious disease (e.g., periodontitis). 14. known immunodeficiency. 15. positive test results for hepatitis b, hepatitis c, hiv antibody. 16. subjects who consume on average more than 3 units of alcohol per day (one alcohol unit =1 beer \[12 oz\] =1 wine \[5 oz\] =1 spirits \[1.5 oz\]) or are unable to abstain from using alcohol during the study
the effect of additional arm therapy on arm function after stroke

Conditions: Stroke

Summary: this study would focus on a new method of adding extra arm exercise to the usual therapy delivered in the hospital. we propose to design an exercise program for the affected arm and hand that would be given to the client as homework and done in the client's hospital room. the program would be designed and monitored by a therapist that works in the hospital. we believe that this program will: 1) increase arm and hand recovery over usual care received in the hospital, 2) help people make the move from therapist run exercise to self management of exercise, and 3) promote family involvement in therapy.

in total 250 participants admitted for stroke rehabilitation at 4 bc sites will be randomly assigned to either the experimental or the control group. the extra arm and hand exercise program (experimental group) will receive usual therapy plus 60 minutes per day of additional arm exercises. this program will last for 4 weeks while the participant is in the hospital. the arm and hand program will include muscle strengthening and stretching, repetitive reaching, folding, stacking, pushing and pulling tasks, picking up objects, and activities that use speed and accuracy. the family will be encouraged to participate in the program with the participant. the control group will receive usual therapy only.

Eligibility criteria:
inclusion criteria: 1. 19 years of age or older 2. arm recovery as a rehabilitation goal 3. have palpatable movement of wrist extension 4. able to follow 3 step verabal commands exclusion criteria: 1. unstable cardiovascular status (congestive heart failure, uncontrolled hypertension, uncontrolled atrial fibrillation, or left ventricular failure), 2. significant musculo-skeletal problems (e.g., rheumatoid arthritis) or neurological conditions (e.g., parkinson's disease) due to conditions other than stroke, 3. receptive aphasia

Keywords: exercise rehabilitation upper limb inpatient rct activities of daily living
liberal use of sodium in ambulatory heart failure

Conditions: Heart Failure

Summary: this study investigates the effects of an increased sodium intake in heart failure patients with reduced ejection fraction and age-matched volunteers without heart failure.

at the start of the study, baseline investigations are performed including assessment of vital signs (blood pressure, heart rate, pulse oxygen saturation), weight, everest congestion score (consisting of grading of dyspnea, orthopnea, jugular venous distention, rales, edema and fatigue), echocardiography, 24h urine collection, bio-impedance measurements and blood sample analysis with plasma renin and aldosterone subsequently, a run-in phase of 2 weeks, without intervention, will start. after this run-in period, participants will be reassessed with the same baseline investigations. in addition, a skin biopsy will be performed as well as a blood volume measurement. in the next phase of the study, salt intake will be increased with 3 grams daily. the salt will be packed in capsules containing 1 g of sodium chloride (nacl). patients will be asked to take one capsule with their breakfast, lunch and dinner. every 2 weeks a follow-up visit is planned. after 4 weeks of increased salt intake, a new skin biopsy will be taken and a blood volume measurement will be performed.

Eligibility criteria:
inclusion criteria: 1. heart failure patients: * left ventricular ejection fraction ≤40% on echocardiogram obtained at inclusion * stable dose of guideline-recommended disease modifying drugs for at least 3 months. * maximum daily loop diuretic dose of 40 mg furosemide equivalents with a stable dose for the last month 2. healthy volunteers: * age \> 60 y * normal ejection fraction (\>50%) without heart failure * no neurohormonal blockers for hypertension * normal nt-probnp exclusion criteria: * heart failure hospitalization for congestion or myocardial infarction in past 3 months * permanent atrial fibrillation * new york heart association (nyha) class iii-iv * estimated glomerular filtration rate (egfr) \< 30 ml/min * signs of congestion * severe right ventricular dysfunction * severe valvular disease * cardiothoracic anatomy not allowing satisfactory and reproducible recordings of echocardiogram * inability to fully comprehend and/or perform study procedures in the investigator's opinion.

Keywords: sodium salt heart failure
periodic use of continuous glucose monitoring with personalized diet interventions using ai camera among non-insulin treated type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the aim of this study is to evaluate the periodic use of continuous glucose monitoring (cgm) with an ai camera and following diet education among non-insulin-treated type 2 diabetes patients.

the control group used self-monitoring blood glucose (smbg) for two weeks with a manual food diary followed by diet education and repeated smbg with a food diary three months later. treatment 1 group used cgm (freestyle libre) for two weeks with an ai food camera followed by diet education, and repeated cgm for two weeks with an ai food camera three months later. treatment 2 group used cgm for two weeks with an ai food camera followed by diet education without repeat three months later. every group followed at 6 months for the final outcome. hba1c at 6 months is the primary outcome.

Eligibility criteria:
inclusion criteria: 1. type 2 diabetes patients 2. hba1c 6.5% - 10% 3. no medication changes in the past 3 months, and receiving treatment with lifestyle modification or oral antidiabetic drugs or glp-1 receptor agonists 4. ages 18 - 80 years old exclusion criteria: 1. insulin users 2. those who have used steroids within the past 3 months or are expected to use them during the study period (excluding ointments) 3. type 1 diabetes patients 4. patients who have undergone pancreatic resection 5. patients undergoing hemodialysis or peritoneal dialysis 6. those requiring continuous mri and ct scans 7. those deemed by the researcher to have difficulty handling continuous glucose monitors and ai cameras 8. those deemed unsuitable for participation in this clinical trial by the investigator, other than those mentioned above 9. pregnant women

Keywords: type 2 diabetes non-insulin continuous glucose monitoring ai camera periodic use
prospective registry of therapeutic endoscopic ultrasound

Conditions: Gastric Outlet Obstruction; Biliary Obstruction; Acute Pancreatic Fluid Collection; Acute Pancreatitis With Infected Necrosis; Acute Cholecystitis; Chronic Pancreatitis

Summary: this registry aims to analyze long-term outcomes of therapeutic eus (t-eus) procedures, as well as to describe clinical and technical variables potentially predicting clinical success or adverse events, for a better selection of ideal candidates.

this is an observational, prospective, single centre study. this registry aims to evaluate long-term clinical success of eus-guided therapeutic interventions (t-eus), as well as adverse events, and clinical and technical variables asociated with clinical success and adverse events. for the purpose of this registry, the following procedures will be considered to be t-eus procedures: * eus-guided collection drainage * eus-guided biliary drainage * eus-guided gallbladder drainage * eus-guided gastro-enterostomy * eus-directed ercp * eus-guided pancreatic duct drainage each patient will be assigned to a procedure following standard clinical practice, in most instances following a routinely multidisciplinary discussion. all patients eligible for the abovementioned clinical indications, but finally undergoing alternative procedures (e.g. surgical interventions, percutaneous interventions or other endoscopic procedures) will be proposed to be enrolled in the registry as "controls". the same variables will be collected, with the exception of technical variables related to the eus-guided intervention.

Eligibility criteria:
inclusion criteria: * subjects candidate to therapeutic eus (t-eus) procedures for any underlying disease * 18 years old or older * able to provide an informed consent to inclusion. exclusion criteria: * age \< 18 years * inability or unwillingness to sign the informed consent form (icf) * contra-indication for endoscopy or use of fluoroscopy

Keywords: endoscopic ultrasound therapeutic eus interventional eus biliary drainage gastro-jejunostomy gallbladder drainage endoscopy